Impact report
In 2025, the diversity of our programmes was showcased with 2 new countries joining our portfolio, whilst others marked more than ten years of NNHF partnership.
Unveiling new horizons
2025 marked a defining moment as we unveiled a new strategic direction – expanding our mission to include haemoglobinopathies while remaining fully committed to haemophilia. Shared with partners worldwide and grounded in lived experience, this evolution reinforces our focus on collaboration and locally led impact: Impacting care together.
The big “Unveiling” at a regional event for Africa, hosted in Nairobi in December 2025.Beyond borders
Angola, Mozambique, and Cape Verde came together to form a coalition advancing haemophilia care across Portuguese-speaking Africa (PALOP). In the Dominican Republic, patient organisations and healthcare professionals from five Latin America and the Caribbean countries united to strengthen care for haemophilia and sickle cell disease.
PALOP ArticleUniting through partnerships
Our strategic partnership with the Novo Nordisk Foundation (NNF) was further strengthened, with a new 5-year agreement that will see NNHF projects quadrupling the number of beneficiaries by 2030. Moreover, our partnership with Fondation Pierre Fabre (FPF) deepened in 2025, strengthening efforts to improve haemophilia and sickle cell disease care.
Programme managers from FPF & NNHF in Kenya during a meeting in Kenya in September 2025.Honouring changemakers
Our 2025 awards for changemakers that remind us that progress is driven by people – committed, courageous, and deeply connected to their communities.
Powered by volunteers
With the help of expert volunteers, we’re able to distribute our expertise and conduct global training sessions.
Apply nowThe invaluable contribution of our expert volunteer: Dr Ofelia Alvarez whose expertise and dedication help build local capacity for our partners in the Dominican Republic, alongside Dr Lusianna Sánchez and Dr Angelica Floren.
Financial Statement
Financial Statements for the year ended 31 December 2025, including the Report of the Statutory Auditor on the Limited Statutory Examination.